市場調査レポート
商品コード
1180655
高カルシウム血症治療の世界市場:成長、将来の見通し、競合分析(2022年~2030年)Hypercalcemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030 |
高カルシウム血症治療の世界市場:成長、将来の見通し、競合分析(2022年~2030年) |
出版日: 2022年08月30日
発行: Acute Market Reports
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
|
世界の高カルシウム血症治療の市場規模は、2021年に136億2,890万米ドルとなり、2022年~2030年の予測期間中に10.7%のCAGRで拡大し、2030年までに338億5,470万米ドルに達すると予測されています。
世界の高カルシウム血症治療市場は、がん患者数の増加、副甲状腺機能亢進症に関連する高カルシウム血症の有病率の上昇、適切な薬物治療療法の可用性などを背景に、予測期間中に急拡大すると考えられます。また、多発性骨髄腫の発症率の上昇、外科手術に代わる薬物療法の可用性、米国を含む先進国における有利な償還政策が、世界市場を活性化すると期待されます。
当レポートでは、世界の高カルシウム血症治療市場について調査分析し、市場動向、競合分析、市場力学、セグメント別・地域別の市場分析、企業プロファイルなど、体系的な情報を提供しています。
Industry Outlook
The global hypercalcemia treatment market will reach US$ 33,854.7 Mn by 2030 from US$ 13,628.9 Mn in 2021, growing at a CAGR of 10.7% during the forecast period from 2022 to 2030. Hypercalcemia is a condition characterized by the elevated levels of serum calcium ranging above 2.6 mmol/L. The disorder is predominantly associated with two main causes including hypercalcemia of malignancy (HCM) and primary hyperparathyroidism. The disorder occurs in 10% to 20% of the cancer patients, prominently in the breast and lung cancer patients. Furthermore, other factors responsible for hypercalcemia are hereditary factors, severe dehydration, medications, and supplements. The global hypercalcemia treatment market will surge during the forecast period pertaining to the rising number of cancer patients, growing prevalence of hyperparathyroidism-related hypercalcemia, and availability of appropriate drug treatment therapies. Furthermore, rising incidence of multiple myeloma, availability of drug therapy alternatives over surgeries and favorable reimbursement policies in developed countries including the United States expected to fuel global market.
As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market. The key market players are particularly focusing on the chronic kidney disease (CKD) along with the parathyroidism. For instance, US FDA approved a drug manufactured by OPKO Health for the treatment of secondary hyperparathyroidism in adults with CKD. Such approvals will propel the growth of global hypercalcemia market.
"Bisphosphonates expected to retain major market share during the forecast period"
Bisphosphonates is the major segment capturing over 65% of market value share. Bisphosphonates are used to prevent the loss of bone density. Due to the high preference of bisphosphonates, the segment will retain its supremacy in the market during the forecast period. Furthermore, the usage of combination therapy for the treatment of hypercalcemia is increasing, which combines two or more drugs from same or different classes. The high preference of combination therapy in developed country further fuels the growth of bisphosphonates market as these drugs are used predominantly in combination therapy with other drugs and therapies. For instance, many researchers and physicians are evaluating the use of combination of pamidronate and calcitonin. Denusomab market segment will be the fastest growing market segment during the forecast period followed by calcitonin. The aforementioned treatment pattern adopted by physicians is expected to catalyze the growth of hypercalcemia drugs market.
"Asia Pacific to Experience Lucrative Growth with Double Digit CAGR during the Forecast Period"
The Asia Pacific expected to witness lucrative growth during the forecast period owing to high awareness and rising adoption of the hypercalcemia treatment drugs. Furthermore, increasing prevalence of hyperparathyroidism-related hypercalcemia and growing incidence of multiple myeloma in the region expected to fuel the market. Additionally, the rising accessibility of drug therapies and favorable reimbursement policies in the developing countries further contributes to the double-digit growth of the Asia Pacific market.
In 2021, North America dominated the hypercalcemia treatment market with over 34% of the market share, in terms of market value. The United States expected to dominate the North America market due to high awareness regarding hypercalcemia and associated disorders. Furthermore, growing prevalence of malignancy-related hypercalcemia among cancer patients will further catalyze the growth of the North America hypercalcemia market.
"Approval of Promising Pipeline Candidates Expected to Fuel the Market Growth"
The global hypercalcemia treatment market is highly fragmented due to the presence of numerous players. However, some of the players dominated the market attributing to the development of effective drugs, novel product launches, and strategic market initiatives. Furthermore, the unmet needs of the disease compel manufacturers to focus on R&D and develop products that are more efficient. For instance, Kyowa Hakko Kirin Co., Ltd. has completed phase III clinical trials for KHK7580 and filled a NDA (New Drug Application) in Japan. Furthermore, the manufacturers is developing another candidate, KRN1493, for secondary hyperparathyroidism. Expected approval of such promising candidates will fuel the market during the forecast period. Additionally, key players in hypercalcemia market include Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin, OPKO Health, Merck & Co., Abbive, Inc., and Pfizer, Inc.
This research study further elucidates the key qualitative market assessment parameters including key market trends, DROs, to assist in holistic understanding of global hypercalcemia treatment market. Additionally, the major players are mapped graphically based on their business strength, market strategies and product offering. The research study further provides attractive investment proposition based on the extensive geographical research. Major manufacturers profiled in the report include AbbVie, Inc., Merck & Co., OPKO Health, Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin and Pfizer, Inc.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hypercalcemia Treatment market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Hypercalcemia Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug
Clodronate
Etidronate
Ibandronate
Pamidronate
Zoledronic acid
Calcimimetic Agents
Calcitonin
Denusomab
Glucocorticoids
Pipeline Analysis
Phase III
KHK7580
Phase II & I (Tabular Information)
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Hypercalcemia Treatment market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Hypercalcemia Treatment market?
Which is the largest regional market for Hypercalcemia Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Hypercalcemia Treatment market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Hypercalcemia Treatment market worldwide?